Search

Your search keyword '"Herpel, Esther"' showing total 785 results
Start Over Author "Herpel, Esther"
785 results on '"Herpel, Esther"'

1. Clinical Characteristics and Outcomes of Colorectal Cancer in the ColoCare Study: Differences by Age of Onset

Author

Himbert, Caroline, Figueiredo, Jane C, Shibata, David, Ose, Jennifer, Lin, Tengda, Huang, Lyen C, Peoples, Anita R, Scaife, Courtney L, Pickron, Bartley, Lambert, Laura, Cohan, Jessica N, Bronner, Mary, Felder, Seth, Sanchez, Julian, Dessureault, Sophie, Coppola, Domenico, Hoffman, David M, Nasseri, Yosef F, Decker, Robert W, Zaghiyan, Karen, Murrell, Zuri A, Hendifar, Andrew, Gong, Jun, Firoozmand, Eiman, Gangi, Alexandra, Moore, Beth A, Cologne, Kyle G, El-Masry, Maryliza S, Hinkle, Nathan, Monroe, Justin, Mutch, Matthew, Bernadt, Cory, Chatterjee, Deyali, Sinanan, Mika, Cohen, Stacey A, Wallin, Ulrike, Grady, William M, Lampe, Paul D, Reddi, Deepti, Krane, Mukta, Fichera, Alessandro, Moonka, Ravi, Herpel, Esther, Schirmacher, Peter, Kloor, Matthias, von Knebel-Doeberitz, Magnus, Nattenmueller, Johanna, Kauczor, Hans-Ulrich, Swanson, Eric, Jedrzkiewicz, Jolanta, Schmit, Stephanie L, Gigic, Biljana, Ulrich, Alexis B, Toriola, Adetunji T, Siegel, Erin M, Li, Christopher I, Ulrich, Cornelia M, and Hardikar, Sheetal

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Digestive Diseases, Colo-Rectal Cancer, Clinical Research, cohort, colorectal cancer, early onset, epidemiology, Oncology and carcinogenesis
Abstract

Early-onset colorectal cancer has been on the rise in Western populations. Here, we compare patient characteristics between those with early- (

Published
2021

2. Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)

Author

Talhouk, Aline, George, Joshy, Wang, Chen, Budden, Timothy, Tan, Tuan Zea, Chiu, Derek S, Kommoss, Stefan, San Leong, Huei, Chen, Stephanie, Intermaggio, Maria P, Gilks, Blake, Nazeran, Tayyebeh M, Volchek, Mila, Elatre, Wafaa, Bentley, Rex C, Senz, Janine, Lum, Amy, Chow, Veronica, Sudderuddin, Hanwei, Mackenzie, Robertson, Leong, Samuel CY, Liu, Geyi, Johnson, Dustin, Chen, Billy, Group, AOCS, Alsop, Jennifer, Banerjee, Susana N, Behrens, Sabine, Bodelon, Clara, Brand, Alison H, Brinton, Louise, Carney, Michael E, Chiew, Yoke-Eng, Cushing-Haugen, Kara L, Cybulski, Cezary, Ennis, Darren, Fereday, Sian, Fortner, Renée T, García-Donas, Jesús, Gentry-Maharaj, Aleksandra, Glasspool, Rosalind, Goranova, Teodora, Greene, Casey S, Haluska, Paul, Harris, Holly R, Hendley, Joy, Hernandez, Brenda Y, Herpel, Esther, Jimenez-Linan, Mercedes, Karpinskyj, Chloe, Kaufmann, Scott H, Keeney, Gary L, Kennedy, Catherine J, Köbel, Martin, Koziak, Jennifer M, Larson, Melissa C, Lester, Jenny, Lewsley, Liz-Anne, Lissowska, Jolanta, Lubiński, Jan, Luk, Hugh, Macintyre, Geoff, Mahner, Sven, McNeish, Iain A, Menkiszak, Janusz, Nevins, Nikilyn, Osorio, Ana, Oszurek, Oleg, Palacios, José, Hinsley, Samantha, Pearce, Celeste L, Pike, Malcolm C, Piskorz, Anna M, Ray-Coquard, Isabelle, Rhenius, Valerie, Rodriguez-Antona, Cristina, Sharma, Raghwa, Sherman, Mark E, De Silva, Dilrini, Singh, Naveena, Sinn, Peter, Slamon, Dennis, Song, Honglin, Steed, Helen, Stronach, Euan A, Thompson, Pamela J, Tołoczko, Aleksandra, Trabert, Britton, Traficante, Nadia, Tseng, Chiu-Chen, Widschwendter, Martin, Wilkens, Lynne R, Winham, Stacey J, Winterhoff, Boris, Beeghly-Fadiel, Alicia, Benitez, Javier, Berchuck, Andrew, Brenton, James D, Brown, Robert, and Chang-Claude, Jenny

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Rare Diseases, Orphan Drug, Genetics, Ovarian Cancer, Women's Health, Cancer Genomics, Precision Medicine, Cancer, Human Genome, 4.2 Evaluation of markers and technologies, Good Health and Well Being, Aged, Algorithms, Cystadenoma, Serous, Female, Gene Expression Regulation, Neoplastic, Humans, Lymphocytes, Tumor-Infiltrating, Middle Aged, Neoplasm Grading, Neoplasm Proteins, Neoplasm, Residual, Ovarian Neoplasms, Transcriptome, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeGene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported subtype-associated features.Experimental designAdopting two independent approaches, we derived and internally validated algorithms for subtype prediction using published gene expression data from 1,650 tumors. We applied resulting models to NanoString data on 3,829 HGSOCs from the Ovarian Tumor Tissue Analysis consortium. We further developed, confirmed, and validated a reduced, minimal gene set predictor, with methods suitable for a single-patient setting.ResultsGene expression data were used to derive the predictor of high-grade serous ovarian carcinoma molecular subtype (PrOTYPE) assay. We established a de facto standard as a consensus of two parallel approaches. PrOTYPE subtypes are significantly associated with age, stage, residual disease, tumor-infiltrating lymphocytes, and outcome. The locked-down clinical grade PrOTYPE test includes a model with 55 genes that predicted gene expression subtype with >95% accuracy that was maintained in all analytic and biological validations.ConclusionsWe validated the PrOTYPE assay following the Institute of Medicine guidelines for the development of omics-based tests. This fully defined and locked-down clinical grade assay will enable trial design with molecular subtype stratification and allow for objective assessment of the predictive value of HGSOC molecular subtypes in precision medicine applications.See related commentary by McMullen et al., p. 5271.

Published
2020

3. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Author

Martins, Filipe Correia, Couturier, Dominique-Laurent, Paterson, Anna, Karnezis, Anthony N, Chow, Christine, Nazeran, Tayyebeh M, Odunsi, Adekunle, Gentry-Maharaj, Aleksandra, Vrvilo, Aleksandra, Hein, Alexander, Talhouk, Aline, Osorio, Ana, Hartkopf, Andreas D, Brooks-Wilson, Angela, DeFazio, Anna, Fischer, Anna, Hartmann, Arndt, Hernandez, Brenda Y, McCauley, Bryan M, Karpinskyj, Chloe, de Sousa, Christiani B, Høgdall, Claus, Tiezzi, Daniel G, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Keeney, Gary, Nelson, Gregg, Steed, Helen, Song, Honglin, Luk, Hugh, Benitez, Javier, Alsop, Jennifer, Koziak, Jennifer M, Lester, Jenny, Rothstein, Joseph H, de Andrade, Jurandyr M, Lundvall, Lene, Paz-Ares, Luis, Robles-Díaz, Luis, Wilkens, Lynne R, Garcia, Maria J, Intermaggio, Maria P, Alcaraz, Marie-Lyne, Brett, Mary A, Beckmann, Matthias W, Jimenez-Linan, Mercedes, Anglesio, Michael, Carney, Michael E, Schneider, Michael, Traficante, Nadia, Pejovic, Nadja, Singh, Naveena, Le, Nhu, Sinn, Peter, Ghatage, Prafull, Erber, Ramona, Edwards, Robert, Vierkant, Robert, Ness, Roberta B, Leung, Samuel, Orsulic, Sandra, Brucker, Sara Y, Kaufmann, Scott H, Fereday, Sian, Gayther, Simon, Winham, Stacey J, Kommoss, Stefan, Pejovic, Tanja, Longacre, Teri A, McGuire, Valerie, Rhenius, Valerie, Sieh, Weiva, Shvetsov, Yurii B, Whittemore, Alice S, Staebler, Annette, Karlan, Beth Y, Rodriguez-Antona, Cristina, Bowtell, David D, Goode, Ellen L, Høgdall, Estrid, Candido Dos Reis, Francisco J, Gronwald, Jacek, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, Fasching, Peter A, Crawford, Robin, Deen, Suha, Menon, Usha, Huntsman, David G, Köbel, Martin, Ramus, Susan J, Pharoah, Paul DP, and Brenton, James D

Subjects
Oncology & Carcinogenesis, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

BackgroundPTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.MethodsTumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests.ResultsDownregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value

Published
2020

5. Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study.

Author

Rambau, Peter F, Vierkant, Robert A, Intermaggio, Maria P, Kelemen, Linda E, Goodman, Marc T, Herpel, Esther, Pharoah, Paul D, Kommoss, Stefan, Jimenez-Linan, Mercedes, Karlan, Beth Y, Gentry-Maharaj, Aleksandra, Menon, Usha, Polo, Susanna Hernando, Candido Dos Reis, Francisco J, Doherty, Jennifer Anne, Gayther, Simon A, Sharma, Raghwa, Larson, Melissa C, Harnett, Paul R, Hatfield, Emma, de Andrade, Jurandyr M, Nelson, Gregg S, Steed, Helen, Schildkraut, Joellen M, Carney, Micheal E, Høgdall, Estrid, Whittemore, Alice S, Widschwendter, Martin, Kennedy, Catherine J, Wang, Frances, Wang, Qin, Wang, Chen, Armasu, Sebastian M, Daley, Frances, Coulson, Penny, Jones, Micheal E, Anglesio, Micheal S, Chow, Christine, de Fazio, Anna, García-Closas, Montserrat, Brucker, Sara Y, Cybulski, Cezary, Harris, Holly R, Hartkopf, Andreas D, Huzarski, Tomasz, Jensen, Allan, Lubiński, Jan, Oszurek, Oleg, Benitez, Javier, Mina, Fady, Staebler, Annette, Taran, Florin Andrei, Pasternak, Jana, Talhouk, Aline, Rossing, Mary Anne, Hendley, Joy, AOCS Group, Edwards, Robert P, Fereday, Sian, Modugno, Francesmary, Ness, Roberta B, Sieh, Weiva, El-Bahrawy, Mona A, Winham, Stacey J, Lester, Jenny, Kjaer, Susanne K, Gronwald, Jacek, Sinn, Peter, Fasching, Peter A, Chang-Claude, Jenny, Moysich, Kirsten B, Bowtell, David D, Hernandez, Brenda Y, Luk, Hugh, Behrens, Sabine, Shah, Mitul, Jung, Audrey, Ghatage, Prafull, Alsop, Jennifer, Alsop, Kathryn, García-Donas, Jesús, Thompson, Pamela J, Swerdlow, Anthony J, Karpinskyj, Chloe, Cazorla-Jiménez, Alicia, García, María J, Deen, Susha, Wilkens, Lynne R, Palacios, José, Berchuck, Andrew, Koziak, Jennifer M, Brenton, James D, Cook, Linda S, Goode, Ellen L, Huntsman, David G, Ramus, Susan J, and Köbel, Martin

Subjects
AOCS Group, Ovary, Humans, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Ovarian Neoplasms, Prognosis, Immunohistochemistry, Survival Rate, Adult, Aged, Middle Aged, Female, Cyclin-Dependent Kinase Inhibitor p16, RT-QPCR, immunocytochemistry, ovary, Adenocarcinoma, Mucinous, Cystadenocarcinoma, Serous, Cancer, Genetics, Ovarian Cancer, Rare Diseases, 2.1 Biological and endogenous factors
Abstract

We aimed to validate the prognostic association of p16 expression in ovarian high-grade serous carcinomas (HGSC) and to explore it in other ovarian carcinoma histotypes. p16 protein expression was assessed by clinical-grade immunohistochemistry in 6525 ovarian carcinomas including 4334 HGSC using tissue microarrays from 24 studies participating in the Ovarian Tumor Tissue Analysis consortium. p16 expression patterns were interpreted as abnormal (either overexpression referred to as block expression or absence) or normal (heterogeneous). CDKN2A (which encodes p16) mRNA expression was also analyzed in a subset (n = 2280) mostly representing HGSC (n = 2010). Association of p16 expression with overall survival (OS) was determined within histotypes as was CDKN2A expression for HGSC only. p16 block expression was most frequent in HGSC (56%) but neither protein nor mRNA expression was associated with OS. However, relative to heterogeneous expression, block expression was associated with shorter OS in endometriosis-associated carcinomas, clear cell [hazard ratio (HR): 2.02, 95% confidence (CI) 1.47-2.77, p < 0.001] and endometrioid (HR: 1.88, 95% CI 1.30-2.75, p = 0.004), while absence was associated with shorter OS in low-grade serous carcinomas (HR: 2.95, 95% CI 1.61-5.38, p = 0.001). Absence was most frequent in mucinous carcinoma (50%), and was not associated with OS in this histotype. The prognostic value of p16 expression is histotype-specific and pattern dependent. We provide definitive evidence against an association of p16 expression with survival in ovarian HGSC as previously suggested. Block expression of p16 in clear cell and endometrioid carcinoma should be further validated as a prognostic marker, and absence in low-grade serous carcinoma justifies CDK4 inhibition.

Published
2018

6. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer.

Author

Block, Matthew S, Vierkant, Robert A, Rambau, Peter F, Winham, Stacey J, Wagner, Philipp, Traficante, Nadia, Tołoczko, Aleksandra, Tiezzi, Daniel G, Taran, Florin Andrei, Sinn, Peter, Sieh, Weiva, Sharma, Raghwa, Rothstein, Joseph H, Ramón Y Cajal, Teresa, Paz-Ares, Luis, Oszurek, Oleg, Orsulic, Sandra, Ness, Roberta B, Nelson, Gregg, Modugno, Francesmary, Menkiszak, Janusz, McGuire, Valerie, McCauley, Bryan M, Mack, Marie, Lubiński, Jan, Longacre, Teri A, Li, Zheng, Lester, Jenny, Kennedy, Catherine J, Kalli, Kimberly R, Jung, Audrey Y, Johnatty, Sharon E, Jimenez-Linan, Mercedes, Jensen, Allan, Intermaggio, Maria P, Hung, Jillian, Herpel, Esther, Hernandez, Brenda Y, Hartkopf, Andreas D, Harnett, Paul R, Ghatage, Prafull, García-Bueno, José M, Gao, Bo, Fereday, Sian, Eilber, Ursula, Edwards, Robert P, de Sousa, Christiani B, de Andrade, Jurandyr M, Chudecka-Głaz, Anita, Chenevix-Trench, Georgia, Cazorla, Alicia, Brucker, Sara Y, Australian Ovarian Cancer Study Group, Alsop, Jennifer, Whittemore, Alice S, Steed, Helen, Staebler, Annette, Moysich, Kirsten B, Menon, Usha, Koziak, Jennifer M, Kommoss, Stefan, Kjaer, Susanne K, Kelemen, Linda E, Karlan, Beth Y, Huntsman, David G, Høgdall, Estrid, Gronwald, Jacek, Goodman, Marc T, Gilks, Blake, García, María José, Fasching, Peter A, de Fazio, Anna, Deen, Suha, Chang-Claude, Jenny, Candido Dos Reis, Francisco J, Campbell, Ian G, Brenton, James D, Bowtell, David D, Benítez, Javier, Pharoah, Paul DP, Köbel, Martin, Ramus, Susan J, and Goode, Ellen L

Subjects
Australian Ovarian Cancer Study Group, Humans, Ovarian Neoplasms, Tissue Array Analysis, Immunohistochemistry, Survival Analysis, Adult, Aged, Middle Aged, Female, Toll-Like Receptor 4, Myeloid Differentiation Factor 88, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Biomarkers, Tumor, Carcinoma, Ovarian Epithelial, Medical and Health Sciences
Abstract

ObjectiveTo evaluate myeloid differentiation primary response gene 88 (MyD88) and Toll-like receptor 4 (TLR4) expression in relation to clinical features of epithelial ovarian cancer, histologic subtypes, and overall survival.Patients and methodsWe conducted centralized immunohistochemical staining, semi-quantitative scoring, and survival analysis in 5263 patients participating in the Ovarian Tumor Tissue Analysis consortium. Patients were diagnosed between January 1, 1978, and December 31, 2014, including 2865 high-grade serous ovarian carcinomas (HGSOCs), with more than 12,000 person-years of follow-up time. Tissue microarrays were stained for MyD88 and TLR4, and staining intensity was classified using a 2-tiered system for each marker (weak vs strong).ResultsExpression of MyD88 and TLR4 was similar in all histotypes except clear cell ovarian cancer, which showed reduced expression compared with other histotypes (P

Published
2018

7. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

Author

Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas D, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Eilber, Ursula, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, deFazio, Anna, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, dos Reis, Francisco J Candido, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, and Ramus, Susan J

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Prevention, Vaccine Related, Rare Diseases, Clinical Research, Ovarian Cancer, BRCA2 Protein, CD8 Antigens, Carcinoma, Ovarian Epithelial, Cohort Studies, Cystadenocarcinoma, Serous, Female, Humans, Lymphocytes, Tumor-Infiltrating, Middle Aged, Mutation, Neoplasm Grading, Ovarian Neoplasms, Prospective Studies, Survival Analysis, Treatment Outcome, Ovarian Tumor Tissue Analysis (OTTA) Consortium, Public Health and Health Services, Oncology and carcinogenesis
Abstract

ImportanceCytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.ObjectiveTo define the prognostic role of CD8+ TILs in epithelial ovarian cancer.Design, setting, and participantsThis was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.ExposuresFollowing immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.Main outcomes and measuresOverall survival time.ResultsThe final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.Conclusions and relevanceThis study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Published
2017

8. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer.

Author

Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode, Ellen L, Block, Matthew S, Kalli, Kimberly R, Vierkant, Robert A, Chen, Wenqian, Fogarty, Zachary C, Gentry-Maharaj, Aleksandra, Tołoczko, Aleksandra, Hein, Alexander, Bouligny, Aliecia L, Jensen, Allan, Osorio, Ana, Hartkopf, Andreas, Ryan, Andy, Chudecka-Głaz, Anita, Magliocco, Anthony M, Hartmann, Arndt, Jung, Audrey Y, Gao, Bo, Hernandez, Brenda Y, Fridley, Brooke L, McCauley, Bryan M, Kennedy, Catherine J, Wang, Chen, Karpinskyj, Chloe, de Sousa, Christiani B, Tiezzi, Daniel G, Wachter, David L, Herpel, Esther, Taran, Florin Andrei, Modugno, Francesmary, Nelson, Gregg, Lubiński, Jan, Menkiszak, Janusz, Alsop, Jennifer, Lester, Jenny, García-Donas, Jesús, Nation, Jill, Hung, Jillian, Palacios, José, Rothstein, Joseph H, Kelley, Joseph L, de Andrade, Jurandyr M, Robles-Díaz, Luis, Intermaggio, Maria P, Widschwendter, Martin, Beckmann, Matthias W, Ruebner, Matthias, Jimenez-Linan, Mercedes, Singh, Naveena, Oszurek, Oleg, Harnett, Paul R, Rambau, Peter F, Sinn, Peter, Wagner, Philipp, Ghatage, Prafull, Sharma, Raghwa, Edwards, Robert P, Ness, Roberta B, Orsulic, Sandra, Brucker, Sara Y, Johnatty, Sharon E, Longacre, Teri A, Ursula, Eilber, McGuire, Valerie, Sieh, Weiva, Natanzon, Yanina, Li, Zheng, Whittemore, Alice S, Anna, deFazio, Staebler, Annette, Karlan, Beth Y, Gilks, Blake, Bowtell, David D, Høgdall, Estrid, Candido dos Reis, Francisco J, Steed, Helen, Campbell, Ian G, Gronwald, Jacek, Benítez, Javier, Koziak, Jennifer M, Chang-Claude, Jenny, Moysich, Kirsten B, Kelemen, Linda E, Cook, Linda S, Goodman, Marc T, García, María José, Fasching, Peter A, Kommoss, Stefan, Deen, Suha, Kjaer, Susanne K, Menon, Usha, Brenton, James D, Pharoah, Paul DP, Chenevix-Trench, Georgia, Huntsman, David G, Winham, Stacey J, Köbel, Martin, and Ramus, Susan J

Subjects
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Lymphocytes, Tumor-Infiltrating, Humans, Cystadenocarcinoma, Serous, Ovarian Neoplasms, BRCA2 Protein, Treatment Outcome, Survival Analysis, Cohort Studies, Prospective Studies, Mutation, Middle Aged, Female, Neoplasm Grading, CD8 Antigens, Carcinoma, Ovarian Epithelial, Lymphocytes, Tumor-Infiltrating, Cystadenocarcinoma, Serous, Carcinoma, Ovarian Epithelial, Cancer, Prevention, Ovarian Cancer, Rare Diseases, Vaccine Related, Clinical Research, Oncology and Carcinogenesis, Public Health and Health Services
Abstract

ImportanceCytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) participate in immune control of epithelial ovarian cancer; however, little is known about prognostic patterns of CD8+ TILs by histotype and in relation to other clinical factors.ObjectiveTo define the prognostic role of CD8+ TILs in epithelial ovarian cancer.Design, setting, and participantsThis was a multicenter observational, prospective survival cohort study of the Ovarian Tumor Tissue Analysis Consortium. More than 5500 patients, including 3196 with high-grade serous ovarian carcinomas (HGSOCs), were followed prospectively for over 24 650 person-years.ExposuresFollowing immunohistochemical analysis, CD8+ TILs were identified within the epithelial components of tumor islets. Patients were grouped based on the estimated number of CD8+ TILs per high-powered field: negative (none), low (1-2), moderate (3-19), and high (≥20). CD8+ TILs in a subset of patients were also assessed in a quantitative, uncategorized manner, and the functional form of associations with survival was assessed using penalized B-splines.Main outcomes and measuresOverall survival time.ResultsThe final sample included 5577 women; mean age at diagnosis was 58.4 years (median, 58.2 years). Among the 5 major invasive histotypes, HGSOCs showed the most infiltration. CD8+ TILs in HGSOCs were significantly associated with longer overall survival; median survival was 2.8 years for patients with no CD8+ TILs and 3.0 years, 3.8 years, and 5.1 years for patients with low, moderate, or high levels of CD8+ TILs, respectively (P value for trend = 4.2 × 10−16). A survival benefit was also observed among women with endometrioid and mucinous carcinomas, but not for those with the other histotypes. Among HGSOCs, CD8+ TILs were favorable regardless of extent of residual disease following cytoreduction, known standard treatment, and germline BRCA1 pathogenic mutation, but were not prognostic for BRCA2 mutation carriers. Evaluation of uncategorized CD8+ TIL counts showed a near-log-linear functional form.Conclusions and relevanceThis study demonstrates the histotype-specific nature of immune infiltration and provides definitive evidence for a dose-response relationship between CD8+ TILs and HGSOC survival. That the extent of infiltration is prognostic, not merely its presence or absence, suggests that understanding factors that drive infiltration will be the key to unraveling outcome heterogeneity in this cancer.

Published
2017

12. Role of Synaptophysin, Chromogranin and CD56 in adenocarcinoma and squamous cell carcinoma of the lung lacking morphological features of neuroendocrine differentiation: a retrospective large-scale study on 1170 tissue samples

Author

Kriegsmann, Katharina, Zgorzelski, Christiane, Muley, Thomas, Christopoulos, Petros, Thomas, Michael, Winter, Hauke, Eichhorn, Martin, Eichhorn, Florian, von Winterfeld, Moritz, Herpel, Esther, Goeppert, Benjamin, Stenzinger, Albrecht, Herth, Felix J. F., Warth, Arne, and Kriegsmann, Mark

Published
2021
Full Text
View/download PDF

13. A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases

Author

Meagher, Nicola S., Wang, Linyuan, Rambau, Peter F., Intermaggio, Maria P., Huntsman, David G., Wilkens, Lynne R., El-Bahrawy, Mona A., Ness, Roberta B., Odunsi, Kunle, Steed, Helen, Herpel, Esther, Anglesio, Michael S., Zhang, Bonnie, Lambie, Neil, Swerdlow, Anthony J., Lubiński, Jan, Vierkant, Robert A., Goode, Ellen L., Menon, Usha, Toloczko-Grabarek, Aleksandra, Oszurek, Oleg, Bilic, Sanela, Talhouk, Aline, García-Closas, Montserrat, Wang, Qin, Tan, Adeline, Farrell, Rhonda, Kennedy, Catherine J., Jimenez-Linan, Mercedes, Sundfeldt, Karin, Etter, John L., Menkiszak, Janusz, Goodman, Marc T., Klonowski, Paul, Leung, Yee, Winham, Stacey J., Moysich, Kirsten B., Behrens, Sabine, Kluz, Tomasz, Edwards, Robert P., Gronwald, Jacek, Modugno, Francesmary, Hernandez, Brenda Y, Chow, Christine, Kelemen, Linda E., Keeney, Gary L., Carney, Michael E., Natanzon, Yanina, Robertson, Gregory, Sharma, Raghwa, Gayther, Simon A., Alsop, Jennifer, Luk, Hugh, Karpinskyj, Chloe, Campbell, Ian, Sinn, Peter, Gentry-Maharaj, Aleksandra, Coulson, Penny, Chang-Claude, Jenny, Shah, Mitul, Widschwendter, Martin, Tang, Katrina, Schoemaker, Minouk J., Koziak, Jennifer M., Cook, Linda S., Brenton, James D., Daley, Frances, Kristjansdottir, Björg, Mateoiu, Constantina, Larson, Melissa C., Harnett, Paul R., Jung, Audrey, deFazio, Anna, Gorringe, Kylie L., Pharoah, Paul D.P., Minoo, Parham, Stewart, Colin, Bathe, Oliver F., Gui, Xianyong, Cohen, Paul, Ramus, Susan J., and Köbel, Martin

Published
2019
Full Text
View/download PDF

15. Metabolomics and transcriptomics identify pathway differences between visceral and subcutaneous adipose tissue in colorectal cancer patients: the ColoCare study 1 , 2

Author

Liesenfeld, David B, Grapov, Dmitry, Fahrmann, Johannes F, Salou, Mariam, Scherer, Dominique, Toth, Reka, Habermann, Nina, Böhm, Jürgen, Schrotz-King, Petra, Gigic, Biljana, Schneider, Martin, Ulrich, Alexis, Herpel, Esther, Schirmacher, Peter, Fiehn, Oliver, Lampe, Johanna W, and Ulrich, Cornelia M

Subjects
Clinical Research, Cancer, Digestive Diseases, Obesity, Nutrition, Colo-Rectal Cancer, Aetiology, 2.1 Biological and endogenous factors, Metabolic and endocrine, Aged, Biomarkers, Carcinoma, Cohort Studies, Colorectal Neoplasms, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Intra-Abdominal Fat, Lipid Metabolism, Male, Metabolomics, Middle Aged, Neoplasm Staging, Oligonucleotide Array Sequence Analysis, Panniculitis, Paraneoplastic Syndromes, Prospective Studies, Subcutaneous Fat, Abdominal, colorectal cancer, obesity, adipose tissue, visceral adiposity, metabolomics, inflammation, Engineering, Medical and Health Sciences, Nutrition & Dietetics
Abstract

BackgroundMetabolic and transcriptomic differences between visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT) compartments, particularly in the context of obesity, may play a role in colorectal carcinogenesis. We investigated the differential functions of their metabolic compositions.ObjectivesBiochemical differences between adipose tissues (VAT compared with SAT) in patients with colorectal carcinoma (CRC) were investigated by using mass spectrometry metabolomics and gene expression profiling. Metabolite compositions were compared between VAT, SAT, and serum metabolites. The relation between patients' tumor stage and metabolic profiles was assessed.DesignPresurgery blood and paired VAT and SAT samples during tumor surgery were obtained from 59 CRC patients (tumor stages I-IV) of the ColoCare cohort. Gas chromatography time-of-flight mass spectrometry and liquid chromatography quadrupole time-of-flight mass spectrometry were used to measure 1065 metabolites in adipose tissue (333 identified compounds) and 1810 metabolites in serum (467 identified compounds). Adipose tissue gene expression was measured by using Illumina's HumanHT-12 Expression BeadChips.ResultsCompared with SAT, VAT displayed elevated markers of inflammatory lipid metabolism, free arachidonic acid, phospholipases (PLA2G10), and prostaglandin synthesis-related enzymes (PTGD/PTGS2S). Plasmalogen concentrations were lower in VAT than in SAT, which was supported by lower gene expression of FAR1, the rate-limiting enzyme for ether-lipid synthesis in VAT. Serum sphingomyelin concentrations were inversely correlated (P = 0.0001) with SAT adipose triglycerides. Logistic regression identified lipids in patients' adipose tissues, which were associated with CRC tumor stage.ConclusionsAs one of the first studies, we comprehensively assessed differences in metabolic, lipidomic, and transcriptomic profiles between paired human VAT and SAT and their association with CRC tumor stage. We identified markers of inflammation in VAT, which supports prior evidence regarding the role of visceral adiposity and cancer.

Published
2015

17. Bovine meat and milk factor protein expression in tumor‐free mucosa of colorectal cancer patients coincides with macrophages and might interfere with patient survival.

Author

Nikitina, Ekaterina, Burk‐Körner, Amelie, Wiesenfarth, Manuel, Alwers, Elizabeth, Heide, Danijela, Tessmer, Claudia, Ernst, Claudia, Krunic, Damir, Schrotz‐King, Petra, Chang‐Claude, Jenny, von Winterfeld, Moritz, Herpel, Esther, Brobeil, Alexander, Brenner, Hermann, Heikenwalder, Mathias, Hoffmeister, Michael, Kopp‐Schneider, Annette, and Bund, Timo

Abstract

Bovine milk and meat factors (BMMFs) are plasmid‐like DNA molecules isolated from bovine milk and serum, as well as the peritumor of colorectal cancer (CRC) patients. BMMFs have been proposed as zoonotic infectious agents and drivers of indirect carcinogenesis of CRC, inducing chronic tissue inflammation, radical formation and increased levels of DNA damage. Data on expression of BMMFs in large clinical cohorts to test an association with co‐markers and clinical parameters were not previously available and were therefore assessed in this study. Tissue sections with paired tumor‐adjacent mucosa and tumor tissues of CRC patients [individual cohorts and tissue microarrays (TMAs) (n = 246)], low‐/high‐grade dysplasia (LGD/HGD) and mucosa of healthy donors were used for immunohistochemical quantification of the expression of BMMF replication protein (Rep) and CD68/CD163 (macrophages) by co‐immunofluorescence microscopy and immunohistochemical scoring (TMA). Rep was expressed in the tumor‐adjacent mucosa of 99% of CRC patients (TMA), was histologically associated with CD68+/CD163+ macrophages and was increased in CRC patients when compared to healthy controls. Tumor tissues showed only low stromal Rep expression. Rep was expressed in LGD and less in HGD but was strongly expressed in LGD/HGD‐adjacent tissues. Albeit not reaching statistical significance, incidence curves for CRC‐specific death were increased for higher Rep expression (TMA), with high tumor‐adjacent Rep expression being linked to the highest incidence of death. BMMF Rep expression might represent a marker and early risk factor for CRC. The correlation between Rep and CD68 expression supports a previous hypothesis that BMMF‐specific inflammatory regulations, including macrophages, are involved in the pathogenesis of CRC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. CD15 is a risk predictor and a novel target in clear cell renal cell carcinoma

Author

Stenzel, Philipp Joachim, primary, Schindeldecker, Mario, additional, Seidmann, Larissa, additional, Herpel, Esther, additional, Hohenfellner, Markus, additional, Hatiboglu, Gencay, additional, Foersch, Sebastian, additional, Porubsky, Stefan, additional, Macher-Goeppinger, Stephan, additional, Roth, Wilfried, additional, and Tagscherer, Katrin Elisabeth, additional

Published
2023
Full Text
View/download PDF

22. Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

Author

Wagner, Nikolaus B., Weide, Benjamin, Gries, Mirko, Reith, Maike, Tarnanidis, Kathrin, Schuermans, Valerie, Kemper, Charlotte, Kehrel, Coretta, Funder, Anne, Lichtenberger, Ramtin, Sucker, Antje, Herpel, Esther, Holland-Letz, Tim, Schadendorf, Dirk, Garbe, Claus, Umansky, Viktor, Utikal, Jochen, and Gebhardt, Christoffer

Published
2019
Full Text
View/download PDF

23. SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer

Author

Xue, Yibo, Meehan, Brian, Fu, Zheng, Wang, Xue Qing D., Fiset, Pierre Olivier, Rieker, Ralf, Levins, Cameron, Kong, Tim, Zhu, Xianbing, Morin, Geneviève, Skerritt, Lashanda, Herpel, Esther, Venneti, Sriram, Martinez, Daniel, Judkins, Alexander R., Jung, Sungmi, Camilleri-Broet, Sophie, Gonzalez, Anne V., Guiot, Marie-Christine, Lockwood, William W., Spicer, Jonathan D., Agaimy, Abbas, Pastor, William A., Dostie, Josée, Rak, Janusz, Foulkes, William D., and Huang, Sidong

Published
2019
Full Text
View/download PDF

27. Data from High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Charoentong, Pornpimol, primary, Suarez-Carmona, Meggy, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Zoernig, Inka, primary, Luedde, Tom, primary, Jaeger, Dirk, primary, Poleszczuk, Jan, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures 1-4 from High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Charoentong, Pornpimol, primary, Suarez-Carmona, Meggy, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Zoernig, Inka, primary, Luedde, Tom, primary, Jaeger, Dirk, primary, Poleszczuk, Jan, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

29. Data from In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Poleszczuk, Jan, primary, Suarez-Carmona, Meggy, primary, Krisam, Johannes, primary, Charoentong, Pornpimol, primary, Valous, Nektarios A., primary, Weis, Cleo-Aron, primary, Tavernar, Luca, primary, Leiss, Florian, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Marx, Alexander, primary, Jäger, Dirk, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

30. Supplementary Methods from High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Charoentong, Pornpimol, primary, Suarez-Carmona, Meggy, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Zoernig, Inka, primary, Luedde, Tom, primary, Jaeger, Dirk, primary, Poleszczuk, Jan, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Data from Prognostic Value of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand (TRAIL) and TRAIL Receptors in Renal Cell Cancer

Author

Macher-Goeppinger, Stephan, primary, Aulmann, Sebastian, primary, Tagscherer, Katrin E., primary, Wagener, Nina, primary, Haferkamp, Axel, primary, Penzel, Roland, primary, Brauckhoff, Antje, primary, Hohenfellner, Markus, primary, Sykora, Jaromir, primary, Walczak, Henning, primary, Teh, Bin T., primary, Autschbach, Frank, primary, Herpel, Esther, primary, Schirmacher, Peter, primary, and Roth, Wilfried, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Figure Legend 1 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro

Author

Kahlert, Christoph, primary, Lahes, Saleh, primary, Radhakrishnan, Praveen, primary, Dutta, Shamik, primary, Mogler, Carolin, primary, Herpel, Esther, primary, Brand, Karsten, primary, Steinert, Gunnar, primary, Schneider, Martin, primary, Mollenhauer, Martin, primary, Reissfelder, Christoph, primary, Klupp, Fee, primary, Fritzmann, Johannes, primary, Wunder, Christina, primary, Benner, Axel, primary, Kloor, Matthias, primary, Huth, Cathrin, primary, Contin, Pietro, primary, Ulrich, Alexis, primary, Koch, Moritz, primary, and Weitz, Jürgen, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Tables 1-6 from High-Throughput Screening of Combinatorial Immunotherapies with Patient-Specific In Silico Models of Metastatic Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Charoentong, Pornpimol, primary, Suarez-Carmona, Meggy, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Zoernig, Inka, primary, Luedde, Tom, primary, Jaeger, Dirk, primary, Poleszczuk, Jan, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Table 2 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro

Author

Kahlert, Christoph, primary, Lahes, Saleh, primary, Radhakrishnan, Praveen, primary, Dutta, Shamik, primary, Mogler, Carolin, primary, Herpel, Esther, primary, Brand, Karsten, primary, Steinert, Gunnar, primary, Schneider, Martin, primary, Mollenhauer, Martin, primary, Reissfelder, Christoph, primary, Klupp, Fee, primary, Fritzmann, Johannes, primary, Wunder, Christina, primary, Benner, Axel, primary, Kloor, Matthias, primary, Huth, Cathrin, primary, Contin, Pietro, primary, Ulrich, Alexis, primary, Koch, Moritz, primary, and Weitz, Jürgen, primary

Published
2023
Full Text
View/download PDF

35. Suppl.Tables and Figures from In Silico Modeling of Immunotherapy and Stroma-Targeting Therapies in Human Colorectal Cancer

Author

Kather, Jakob Nikolas, primary, Poleszczuk, Jan, primary, Suarez-Carmona, Meggy, primary, Krisam, Johannes, primary, Charoentong, Pornpimol, primary, Valous, Nektarios A., primary, Weis, Cleo-Aron, primary, Tavernar, Luca, primary, Leiss, Florian, primary, Herpel, Esther, primary, Klupp, Fee, primary, Ulrich, Alexis, primary, Schneider, Martin, primary, Marx, Alexander, primary, Jäger, Dirk, primary, and Halama, Niels, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Table 1 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro

Author

Kahlert, Christoph, primary, Lahes, Saleh, primary, Radhakrishnan, Praveen, primary, Dutta, Shamik, primary, Mogler, Carolin, primary, Herpel, Esther, primary, Brand, Karsten, primary, Steinert, Gunnar, primary, Schneider, Martin, primary, Mollenhauer, Martin, primary, Reissfelder, Christoph, primary, Klupp, Fee, primary, Fritzmann, Johannes, primary, Wunder, Christina, primary, Benner, Axel, primary, Kloor, Matthias, primary, Huth, Cathrin, primary, Contin, Pietro, primary, Ulrich, Alexis, primary, Koch, Moritz, primary, and Weitz, Jürgen, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Figure 2 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro

Author

Kahlert, Christoph, primary, Lahes, Saleh, primary, Radhakrishnan, Praveen, primary, Dutta, Shamik, primary, Mogler, Carolin, primary, Herpel, Esther, primary, Brand, Karsten, primary, Steinert, Gunnar, primary, Schneider, Martin, primary, Mollenhauer, Martin, primary, Reissfelder, Christoph, primary, Klupp, Fee, primary, Fritzmann, Johannes, primary, Wunder, Christina, primary, Benner, Axel, primary, Kloor, Matthias, primary, Huth, Cathrin, primary, Contin, Pietro, primary, Ulrich, Alexis, primary, Koch, Moritz, primary, and Weitz, Jürgen, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 1 from Overexpression of ZEB2 at the Invasion Front of Colorectal Cancer Is an Independent Prognostic Marker and Regulates Tumor Invasion In Vitro

Author

Kahlert, Christoph, primary, Lahes, Saleh, primary, Radhakrishnan, Praveen, primary, Dutta, Shamik, primary, Mogler, Carolin, primary, Herpel, Esther, primary, Brand, Karsten, primary, Steinert, Gunnar, primary, Schneider, Martin, primary, Mollenhauer, Martin, primary, Reissfelder, Christoph, primary, Klupp, Fee, primary, Fritzmann, Johannes, primary, Wunder, Christina, primary, Benner, Axel, primary, Kloor, Matthias, primary, Huth, Cathrin, primary, Contin, Pietro, primary, Ulrich, Alexis, primary, Koch, Moritz, primary, and Weitz, Jürgen, primary

Published
2023
Full Text
View/download PDF

40. Data from Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy

Author

Halama, Niels, primary, Michel, Sara, primary, Kloor, Matthias, primary, Zoernig, Inka, primary, Benner, Axel, primary, Spille, Anna, primary, Pommerencke, Thora, primary, von Knebel, Doeberitz Magnus, primary, Folprecht, Gunnar, primary, Luber, Birgit, primary, Feyen, Nadine, primary, Martens, Uwe M., primary, Beckhove, Philipp, primary, Gnjatic, Sacha, primary, Schirmacher, Peter, primary, Herpel, Esther, primary, Weitz, Juergen, primary, Grabe, Niels, primary, and Jaeger, Dirk, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Table 6 from Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Author

Baer, Constance, primary, Claus, Rainer, primary, Frenzel, Lukas P., primary, Zucknick, Manuela, primary, Park, Yoon Jung, primary, Gu, Lei, primary, Weichenhan, Dieter, primary, Fischer, Martina, primary, Pallasch, Christian Philipp, primary, Herpel, Esther, primary, Rehli, Michael, primary, Byrd, John C., primary, Wendtner, Clemens-Martin, primary, and Plass, Christoph, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table 2 from Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Author

Baer, Constance, primary, Claus, Rainer, primary, Frenzel, Lukas P., primary, Zucknick, Manuela, primary, Park, Yoon Jung, primary, Gu, Lei, primary, Weichenhan, Dieter, primary, Fischer, Martina, primary, Pallasch, Christian Philipp, primary, Herpel, Esther, primary, Rehli, Michael, primary, Byrd, John C., primary, Wendtner, Clemens-Martin, primary, and Plass, Christoph, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Table 4 from Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Author

Baer, Constance, primary, Claus, Rainer, primary, Frenzel, Lukas P., primary, Zucknick, Manuela, primary, Park, Yoon Jung, primary, Gu, Lei, primary, Weichenhan, Dieter, primary, Fischer, Martina, primary, Pallasch, Christian Philipp, primary, Herpel, Esther, primary, Rehli, Michael, primary, Byrd, John C., primary, Wendtner, Clemens-Martin, primary, and Plass, Christoph, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figures 1-5 from Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Author

Baer, Constance, primary, Claus, Rainer, primary, Frenzel, Lukas P., primary, Zucknick, Manuela, primary, Park, Yoon Jung, primary, Gu, Lei, primary, Weichenhan, Dieter, primary, Fischer, Martina, primary, Pallasch, Christian Philipp, primary, Herpel, Esther, primary, Rehli, Michael, primary, Byrd, John C., primary, Wendtner, Clemens-Martin, primary, and Plass, Christoph, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Table 5 from Extensive Promoter DNA Hypermethylation and Hypomethylation Is Associated with Aberrant MicroRNA Expression in Chronic Lymphocytic Leukemia

Author

Baer, Constance, primary, Claus, Rainer, primary, Frenzel, Lukas P., primary, Zucknick, Manuela, primary, Park, Yoon Jung, primary, Gu, Lei, primary, Weichenhan, Dieter, primary, Fischer, Martina, primary, Pallasch, Christian Philipp, primary, Herpel, Esther, primary, Rehli, Michael, primary, Byrd, John C., primary, Wendtner, Clemens-Martin, primary, and Plass, Christoph, primary

Published
2023
Full Text
View/download PDF

48. Data from Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer

Author

Singer, Stephan, primary, Malz, Mona, primary, Herpel, Esther, primary, Warth, Arne, primary, Bissinger, Michaela, primary, Keith, Martina, primary, Muley, Thomas, primary, Meister, Michael, primary, Hoffmann, Hans, primary, Penzel, Roland, primary, Gdynia, Georg, primary, Ehemann, Volker, primary, Schnabel, Philipp Albert, primary, Kuner, Ruprecht, primary, Huber, Peter, primary, Schirmacher, Peter, primary, and Breuhahn, Kai, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 1 from Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer

Author

Singer, Stephan, primary, Malz, Mona, primary, Herpel, Esther, primary, Warth, Arne, primary, Bissinger, Michaela, primary, Keith, Martina, primary, Muley, Thomas, primary, Meister, Michael, primary, Hoffmann, Hans, primary, Penzel, Roland, primary, Gdynia, Georg, primary, Ehemann, Volker, primary, Schnabel, Philipp Albert, primary, Kuner, Ruprecht, primary, Huber, Peter, primary, Schirmacher, Peter, primary, and Breuhahn, Kai, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 4 from Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer

Author

Singer, Stephan, primary, Malz, Mona, primary, Herpel, Esther, primary, Warth, Arne, primary, Bissinger, Michaela, primary, Keith, Martina, primary, Muley, Thomas, primary, Meister, Michael, primary, Hoffmann, Hans, primary, Penzel, Roland, primary, Gdynia, Georg, primary, Ehemann, Volker, primary, Schnabel, Philipp Albert, primary, Kuner, Ruprecht, primary, Huber, Peter, primary, Schirmacher, Peter, primary, and Breuhahn, Kai, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results